FORM 4

Check this box if no

16. Form 4 or Form 5

continue. See Instruction

obligations may

1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

longer subject to Section STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB 3235-0287 Number: December 31, Expires: 2014 Estimated average burden hours per

0.5

OMB APPROVAL

response

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Silver David Samuel			2. Issuer Name and Ticker or Trading Symbol Targeted Medical Pharma, Inc. [NONE]	5. Relationship of Reporting Person(s) to Issuer				
(Last) C/O TARGE INC., 2980 B SUITE 301		(Middle) AL PHARMA, EN CIRCLE,	3. Date of Earliest Transaction (Month/Day/Year) 12/21/2011	(Check all applicable) X Director 10% Owner Officer (give (specify below)) See Remarks				
(Street) LOS ANGELES CA 90077 (City) (State) (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date,	3. Transac Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Securities Beneficially Owned	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
			Code	V	Amount (D) Price		Following Reported Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)	(Instr. 4)		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)			Number of Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option to Purchase Common Stock (Right to Buy)	\$ 3.38	12/21/2011		A		400,000		(1)	(1)	Common Stock	400,000	\$ 0	400,000	D	

Explanation of Responses:

1. The option became exercisable as to 200,000 of the shares on December 21, 2011. The option will become exercisable as to an additional 200,000 shares on December 21, 2012. The expiration date for these options is 10 years after they vest. Accordingly, the expiration dates are December 21, 2021 and December 21, 2022, respectively.

Remarks:

Executive Vice President of Medical and Scientific Affairs

/s/ David S. Silver 12/29/2011

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.